Ovarian Tissue Cryopreservation in Korea

At a Glance

Overview

Ovarian tissue cryopreservation (OTC) is a fertility preservation technique primarily designed for patients facing gonadotoxic cancer treatments such as chemotherapy or pelvic radiotherapy. It is currently the only method available to preserve fertility in pre-pubertal girls and in adult women who cannot undergo ovarian stimulation before urgent treatment begins.

The procedure involves laparoscopically removing ovarian cortex strips — the thin outer layer of the ovary that contains immature follicles. These strips are processed in a laboratory and cryopreserved, typically at temperatures below −190°C in liquid or vapour nitrogen.

When the patient is ready to attempt pregnancy — often years or even decades later — the thawed tissue is surgically retransplanted, usually to the remaining ovary or a peritoneal window in the pelvis.

Most retransplants restore spontaneous ovarian endocrine function within 3–6 months, and natural conception without IVF has been documented following successful retransplantation.

The European Society of Human Reproduction and Embryology (ESHRE) recognizes OTC as an established fertility preservation option, no longer experimental, for appropriate candidates. Korean reproductive medicine centers follow international ESHRE-aligned protocols and have documented successful OTC cases.

Am I a Candidate?

OTC is most appropriate for patients in these situations:

• Cancer diagnoses requiring immediate gonadotoxic treatment — breast cancer, lymphoma, leukemia, cervical cancer, and others — where ovarian stimulation delay is not clinically acceptable.
• Pre-pubertal girls facing chemotherapy or bone marrow transplant conditioning, for whom egg or embryo freezing is not possible.
• Women with conditions causing premature ovarian insufficiency, such as Turner syndrome mosaicism or certain autoimmune disorders, who wish to preserve ovarian endocrine and reproductive function.
• Women who are poor responders to ovarian stimulation, where tissue banking may complement or replace egg freezing.

Patients who are not ideal candidates include those with cancers that carry a risk of ovarian metastasis (certain leukemias, advanced ovarian cancer), where retransplanting the tissue could reintroduce malignant cells. A multidisciplinary oncology-reproductive medicine team assessment is required before proceeding.

Age, ovarian reserve, cancer type, and chemotherapy protocol all factor into the candidacy evaluation. In Korean academic hospitals, an oncofertility consultation — involving both the oncology team and reproductive endocrinologists — is standard practice before scheduling retrieval.

How the Procedure Works

The OTC procedure unfolds in two distinct phases: retrieval and cryopreservation, then later retransplantation.

Retrieval phase:

• Pre-operative evaluation includes pelvic ultrasound, anti-Müllerian hormone (AMH) testing, and oncology review.
• Under general anesthesia, a laparoscope is inserted through small abdominal incisions.
• The surgeon removes one ovary or harvests cortex strips from one or both ovaries, depending on the patient's ovarian reserve and clinical needs.
• The harvested tissue is transported immediately to the cryo laboratory in a temperature-controlled medium.
• In the lab, cortex strips are dissected to approximately 1–2 mm thickness to maximize cryoprotectant penetration.
• Strips are cryopreserved using either slow-freeze (controlled-rate cooling) or vitrification (ultra-rapid freezing) protocols, then stored in liquid nitrogen.

Retransplantation phase (a separate future procedure):

• Once the patient is in remission and ready to conceive, thawed tissue strips are sutured orthotopically (onto the remaining ovary) or heterotopically (to a peritoneal pocket or subcutaneous site).
• Laparoscopic orthotopic retransplantation is the standard approach in Korea and internationally, as it allows for natural conception.
• Ovarian function typically resumes within 3–6 months post-retransplantation, confirmed by ultrasound follicle monitoring and hormone levels.

Recovery Timeline

Recovery from the retrieval procedure is generally straightforward:

• Day 0–1: Overnight hospital observation, pain managed with standard analgesics, monitoring for laparoscopic complications.
• Day 2–5: Discharge with activity restrictions; most patients describe discomfort similar to a minor laparoscopic surgery.
• Week 1: Light activity permitted; heavy lifting and strenuous exercise avoided.
• Week 2–4: Full return to daily activities for most patients; oncology treatment may begin within days of discharge if clinically urgent.

For international patients coordinating OTC with cancer treatment in their home country, the typical Korea stay covers the retrieval procedure only. The tissue is stored indefinitely in Korea until the patient returns for retransplantation.

Retransplantation recovery (a separate future visit) follows a similar post-laparoscopic timeline. After retransplantation, ovarian function monitoring begins at approximately 4–6 weeks and continues until follicular activity is confirmed. Patients should plan a follow-up visit or arrange monitoring with a local reproductive endocrinologist in their home country.

Cost

Costs vary by hospital and case. Ask the hospital for a written, itemised estimate before you decide.

Why Korea

Korea has developed particular strength in reproductive medicine and laparoscopic gynecologic surgery, concentrated in major teaching hospitals in Seoul and Busan.

Laparoscopic surgical expertise is a core driver. Korean gynecologic surgeons perform high volumes of minimally invasive procedures, and the infrastructure for same-session surgical-to-laboratory tissue handoff — critical for OTC — is well established at academic medical centers.

Cryo laboratory standards at Korean reproductive medicine programs align with international benchmarks. The Korea Health Industry Development Institute (KHIDI) supports international patient coordination under the Medical Korea framework, and facilities treating foreign patients are subject to oversight by the Ministry of Food and Drug Safety (MFDS).

Oncofertility as a subspecialty has grown alongside Korea's oncology sector. The country's tertiary hospitals manage high case volumes of breast cancer, cervical cancer, and hematologic malignancies — the same diagnoses most commonly referred for OTC. This means the multidisciplinary team (oncologist, reproductive endocrinologist, embryologist) works within an integrated clinical environment.

International patient infrastructure is a real advantage. Major Seoul hospitals with reproductive medicine programs have English-language international patient centers, dedicated coordinator teams, and established relationships with KHIDI's Medical Korea patient support network.

Turnaround from consultation to retrieval can often be arranged within a compressed timeline — important for oncology patients who cannot delay treatment.

Cost remains favorable relative to US and UK programs, without meaningful compromise on laboratory or surgical standards.

Related Topics

Sources

• The Experience of Fertility Preservation in a Single Tertiary Center in Korea — PMC
• Ovarian tissue cryopreservation and transplantation in patients with cancer — PMC
• Cryopreservation of ovarian tissue — Frontiers in Reproductive Health
• Fresh and cryopreserved ovarian tissue transplantation: systematic review — PMC

Hospitals offering Ovarian Tissue Cryopreservation